)
Edge20 Mar 2026
Tetra Pak: The Shape of Innovation
The story of Tetra Pak, the Rausing family, and how a paper tetrahedron gave rise to a company that now delivers almost 180 billion packages a year.
Apimeds Pharmaceuticals
Apimeds Pharmaceuticals (APUS) investor relations material
Apimeds Pharmaceuticals has been acquired
Apimeds Pharmaceuticals Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary12 Nov, 2025
Executive summary
Clinical-stage biopharma focused on Apitox, a bee venom-based therapeutic for osteoarthritis and multiple sclerosis, with exclusive U.S. rights and ongoing FDA approval efforts.
Completed IPO in May 2025, raising $11.9 million in net proceeds to fund operations and R&D.
No revenue generated to date; operations funded by equity and related party debt.
Financial highlights
Net loss of $1.78 million for Q3 2025, up from $0.33 million in Q3 2024; net loss of $4.85 million for the nine months ended September 30, 2025, up from $1.08 million year-over-year.
Operating expenses for Q3 2025: $619,693 in R&D and $1,224,546 in G&A, both significantly higher than prior year.
Cash balance of $6.99 million as of September 30, 2025, compared to $3,455 at December 31, 2024.
No revenue recognized in the reporting periods.
Outlook and guidance
Cash on hand and IPO proceeds expected to fund operations for at least 12 months from the reporting date.
Management anticipates continued operating losses as R&D and regulatory activities progress.
Strategic rationale for $700k waiver payment
Actions to address internal control weaknesses
Apitox MS clinical trial timeline?
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Apimeds Pharmaceuticals
- IPO aims to fund late-stage trials for a novel bee venom therapy, but risks remain high.APUS
Registration Filing29 Nov 2025 - IPO funds Phase III trials for novel OA/MS therapy; high risk, no revenue, major owner controls.APUSRegistration Filing29 Nov 2025
- IPO aims to fund late-stage trials for a novel bee venom therapy targeting OA and MS.APUSRegistration Filing29 Nov 2025
- IPO funds will advance Apitox clinical trials for OA and MS amid high risk and no revenue.APUSRegistration Filing29 Nov 2025
- IPO funds pivotal Apitox trials for OA/MS; no US revenue, high risk, major shareholder control.APUSRegistration Filing29 Nov 2025
- IPO targets $16.1M to fund Phase III OA trial for bee venom therapy; high risk, no revenue.APUSRegistration Filing29 Nov 2025
- IPO aims to fund U.S. trials for bee venom therapy; high risk, no revenue, majority control.APUSRegistration Filing29 Nov 2025
- IPO aims to fund late-stage trials for a novel bee venom therapy in OA and MS.APUSRegistration Filing29 Nov 2025
- Apitox's clinical success and market exclusivity drive strong growth prospects in pain management.APUSCorporate Presentation2 Sep 2025
Apimeds Pharmaceuticals
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage